| 22.5 -0.14 (-0.62%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 28.84 | 1-year : | 33.69 |
| Resists | First : | 24.7 | Second : | 28.84 |
| Pivot price | 21.59 |
|||
| Supports | First : | 21.47 | Second : | 19.47 |
| MAs | MA(5) : | 21.99 |
MA(20) : | 21.62 |
| MA(100) : | 20.23 |
MA(250) : | 12.51 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 81.1 |
D(3) : | 73.3 |
| RSI | RSI(14): 53  |
|||
| 52-week | High : | 27.71 | Low : | 4.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLN ] has closed below upper band by 10.7%. Bollinger Bands are 44.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 22.89 - 23 | 23 - 23.08 |
| Low: | 22.01 - 22.17 | 22.17 - 22.27 |
| Close: | 22.28 - 22.51 | 22.51 - 22.66 |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Mon, 22 Apr 2024
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock - Silence Therapeutics (NASDAQ:SLN) - Benzinga
Mon, 15 Apr 2024
Silence Therapeutics Announces Upcoming AGM - TipRanks.com - TipRanks
Fri, 12 Apr 2024
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
Mon, 08 Apr 2024
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated ... - Business Wire
Tue, 19 Mar 2024
With 28% ownership, Silence Therapeutics plc (NASDAQ:SLN) insiders have a lot riding on the company's future - Simply Wall St
Sat, 16 Mar 2024
Analysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 17 (%) |
| Held by Institutions | 44.5 (%) |
| Shares Short | 93 (K) |
| Shares Short P.Month | 46 (K) |
| EPS | -1.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | -170.6 % |
| Operating Margin | -633.6 % |
| Return on Assets (ttm) | -30.8 % |
| Return on Equity (ttm) | -221.2 % |
| Qtrly Rev. Growth | -56 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.54 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -15.52 |
| PEG Ratio | 0 |
| Price to Book value | 52.32 |
| Price to Sales | 41.32 |
| Price to Cash Flow | -26.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|